Mathew Varna, Deepthi Bobbity, Krishnasamy Sudarsan, Yadav Prabhaker, Sravani Madhileti, Ramprabhu Gopalan Suresh, Bhatt Girish Chandra, Mandal Kausik, Krishnamurthy Sriram
Pediatric Nephrology Services, Department of Pediatrics, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, 605006, India.
Department of Systems Biology, Centre of Biomedical Research, SGPGIMS Campus, Lucknow, India.
Pediatr Nephrol. 2025 Jun;40(6):1915-1927. doi: 10.1007/s00467-025-06656-x. Epub 2025 Jan 25.
Limited research exists regarding the genetic profile, clinical characteristics, and outcomes of refractory rickets in children from India.
Patients with refractory rickets aged ≤ 18 years were enrolled. Data regarding clinical features, etiology, genotype-phenotype correlation, and estimated glomerular filtration rate (eGFR) were recorded.
Seventy-two patients with refractory rickets (non-nutritional, with normal kidney function at presentation) from 65 families attending the pediatric nephrology clinic from 2005-2024 were included. Median (IQR) age at first presentation was 2 (1, 4) years. Clinical features included failure-to-thrive (49 [68.1%]), polyuria (37 [51.4%]), nephrocalcinosis (33 [45.8%]), fractures (10 [13.9%]), and hypokalemic paralysis (4 [5.6%]). Major etiologies included distal renal tubular acidosis (dRTA) [34(47.2%)], hereditary hypophosphatemic rickets (11 [15.3%]), cystinosis (9 [12.5%]), Lowe syndrome (3 [4.2%]), vitamin D-dependent rickets (4 [5.5%]), and Fanconi-Bickel syndrome (3 [4.2%]). Next-generation sequencing identified 61 variants among 71 children tested (85.9%), of which 56 variants (among 55 children) were pathogenic (P)/likely-pathogenic (LP) (77.5% diagnostic-yield). P/LP variants included SLC4A1 (n = 14), CTNS (n = 9), PHEX (n = 8), WDR72 (n = 5), OCRL (n = 2), SLC2A2 (n = 3), ATP6V0A4 (n = 4), VDR (n = 3), CLDN16 (n = 2), ATP6V1B1 (n = 1), SLC12A1 (n = 1), CLCN5 (n = 1), SLC34A3 (n = 1), ATP7B (n = 1), and KCNJ1 (n = 1). Fifteen novel P/LP variants and five novel variants-of-uncertain-significance (VUS) were identified. c.2573C > A in exon 19 among SLC4A1-dRTA (n = 14) was a recurrent mutation. Five patients with cystinosis, two patients with SLC4A1-dRTA, two with WDR72-dRTA, and two with Bartter syndrome showed progression to CKD stage 2 or greater during follow-up.
dRTA, X-linked hypophosphatemic rickets, and cystinosis were common causes of refractory rickets. The c.2573C > A variant in exon 19 was a recurrent mutation in SLC4A1-dRTA.
关于印度儿童难治性佝偻病的基因图谱、临床特征和预后的研究有限。
纳入年龄≤18岁的难治性佝偻病患者。记录临床特征、病因、基因型-表型相关性及估算肾小球滤过率(eGFR)数据。
纳入了2005年至2024年期间到儿科肾脏病门诊就诊的65个家庭中的72例难治性佝偻病患者(非营养性,初诊时肾功能正常)。首次就诊时的中位(四分位间距)年龄为2(1,4)岁。临床特征包括生长发育迟缓(49例[68.1%])、多尿(37例[51.4%])、肾钙质沉着症(33例[45.8%])、骨折(10例[13.9%])和低钾性麻痹(4例[5.6%])。主要病因包括远端肾小管酸中毒(dRTA)[34例(47.2%)]、遗传性低磷性佝偻病(11例[15.3%])、胱氨酸病(9例[12.5%])、 Lowe综合征(3例[4.2%])、维生素D依赖性佝偻病(4例[5.5%])和范科尼-比克尔综合征(3例[4.2%])。下一代测序在71例检测儿童中鉴定出61个变异(85.9%),其中56个变异(55例儿童中)为致病性(P)/可能致病性(LP)(诊断率77.5%)。P/LP变异包括SLC4A1(n = 14)、CTNS(n = 9)、PHEX(n = 8)、WDR72(n = 5)、OCRL(n = 2)、SLC2A2(n = 3)、ATP6V0A4(n = 4)、VDR(n = 3)、CLDN16(n = 2)、ATP6V1B1(n = 1)、SLC12A1(n = 1)、CLCN5(n = 1)、SLC34A3(n = 1)、ATP7B(n = 1)和KCNJ1(n = 1)。鉴定出15个新的P/LP变异和5个意义未明的新变异(VUS)。SLC4A1-dRTA(n = 14)中第19外显子的c.2573C>A是一个反复出现的突变。5例胱氨酸病患者、2例SLC4A1-dRTA患者、2例WDR72-dRTA患者和2例巴特综合征患者在随访期间进展至慢性肾脏病2期或更严重阶段。
dRTA、X连锁低磷性佝偻病和胱氨酸病是难治性佝偻病的常见病因。第19外显子的c.2573C>A变异是SLC4A1-dRTA中反复出现的突变。